Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Bortezomib (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2018 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2021.
- 21 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.